SAN FRANCISCO, Sept. 14 /PRNewswire-FirstCall/ -- Nile Therapeutics, Inc. , a company focused on the development of novel therapeutics for heart failure patients, today announced that there will be a poster presented at the 13th Annual Scientific Meeting of the Heart Failure Society of America in Boston.
"We believe that these data are very promising, and highlight the potential renal benefits of CD-NP compared with existing heart failure medications," said Joshua Kazam, CEO of Nile Therapeutics. "We look forward to seeing how these results translate to an acute heart failure population in our ongoing Phase II study."
About Nile Therapeutics
Nile Therapeutics, Inc. is a clinical-stage biopharmaceutical company that develops innovative products for the treatment of cardiovascular disease and other areas of unmet medical needs. Nile is initially focusing its efforts on developing its lead compound, CD-NP, a novel rationally designed chimeric peptide in clinical studies for the treatment of heart failure, and CU-NP, a novel rationally designed natriuretic peptide. More information on Nile can be found at http://www.nilethera.com.
Nile Therapeutics, Inc.
